

[Presentations and recording now available]

Second #Webinar: Thematic Network led by the European Association of Health Law - the Interest group on Supranational Biolaw

“Regulatory possibilities to enhance cooperation among the EU’s governance structures and complementarity within the EU acquis”

The webinar on "Regulatory possibilities to enhance cooperation among the EU’s governance structures and complementarity within the EU acquis" took place on Monday 10 January 2022, 11.00 - 12.30 CET, Brussels time.

- The **presentations** are available on the EU Health Policy Platform – Agora network. To access, please register first following this [link](#) (use/create your EU login). Once your request of access has been approved, you will receive a confirmation email. You will then be able to have a look to the presentations, available in this [post](#) on the Platform.
- **Watch the recording until 17 January**, available under this [link](#). Use this password to watch it: @HPP_webinar2022

Description of this webinar:

This second webinar revolved around the EU regulatory possibilities in the field of health for developing an inclusive and equitable EU pharmaceutical strategy. Starting from the role of the European Commission, particularly of DG Santé in building cooperation among EU agencies (including the future HERA) and other parts of the European Commission more centrally in the EU’s governance structures, this webinar discussed the EU dynamics in approaching health and problematising health issues, notably in the context of the pandemic and vaccine strategy.

It also considered the question of the EU competence and its potential, be it with or without Treaty revision, both from an internal perspective within the EU, but also from an external/global perspective of how the EU can promote equitable access to pharmaceuticals in less economically developed countries outside the EU. A few specific examples of these regulatory challenges will be explored in more detail in order to evaluate the complementarity and interoperability of the EU’s legal framework (‘acquis’) on medicines with, for instance, the one applicable to patents, or the one applicable to genetically modified organisms.